chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
CHILDREN'S ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) by GSK. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and 1 more indications. First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
Children's Advil Allergy Sinus is a fixed-dose oral suspension combining ibuprofen (NSAID), chlorpheniramine maleate (first-generation antihistamine), and pseudoephedrine HCl (decongestant) for pediatric patients. It treats upper respiratory allergy symptoms including rhinorrhea, pruritus, lacrimation, and nasopharyngeal congestion in children with hay fever and environmental allergies. The combination addresses multiple symptom pathways: antihistamine blocks H1 receptors to reduce allergic response, NSAID provides analgesic/anti-inflammatory action, and decongestant causes nasal vasoconstriction.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating transition planning and potential team consolidation for the brand.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHILDREN'S ADVIL ALLERGY SINUS at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Children's Advil Allergy Sinus offers limited career growth given LOE approaching status and zero linked job postings; roles focus on defensive brand maintenance, compliance, and eventual transition to generic/private-label management. Career progression is constrained; professionals should expect team downsizing and redeployment post-LOE.